GlassScriptPhysician profile
Joann O Caley
NPI 1396300786
$4,382.04
in general payments reported to CMS, 2019-2025
28 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $921 · 2022: $1,113 · 2023: $234 · 2024: $875 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.25 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $740.13 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $733.84 | 2024-2025 | Lumryz |
| Inspire Medical Systems, INC. | $569.43 | 2023-2025 | Inspire |
| Baxter Healthcare | $378.81 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Advanced Respiratory, INC | $306.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $246.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $183.62 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $147.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $136.16 | 2022-2025 | |
| Grifols USA, LLC | $129.82 | 2021-2022 | |
| Mylan Specialty L.P. | $71.85 | 2021-2022 | |
| Zoll Respicardia, INC. | $66.28 | 2025 | Remede System |
| Philips North America LLC | $59.34 | 2022-2025 | Dreamwear |
| Takeda Pharmaceuticals U.S.A., INC. | $54.46 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $45.81 | 2021 | |
| Paratek Pharmaceuticals, INC. | $35.76 | 2021-2022 | |
| Genzyme Corporation | $35.14 | 2022 | |
| Insmed, INC. | $35.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.89 | 2023 | Quviviq |
| Lilly USA, LLC | $19.54 | 2025 | Zepbound |
| Eisai INC. | $19.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.20 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.23 | 2022 | |
| Amgen INC. | $15.38 | 2022 | |
| 3b Medical, INC. | $14.18 | 2025 | Luna |
| Apria Healthcare LLC | $13.54 | 2021 | |
| Inogen, INC. | $5.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Caley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.